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The monospecific and bivalent characteristics of naturally occurring immunoglobulin G 
(IgG) antibodies depend on homodimerization of the fragment crystallizable (Fc) regions 
of two identical heavy chains (HCs) and the subsequent assembly of two identical 
light chains (LCs) via disulfide linkages between each HC and LC. Immunoglobulin Fc 
heterodimers have been engineered through modifications to the CH3 domain inter-
face, with different mutations on each domain such that the engineered Fc fragments, 
carrying the CH3 variant pair, preferentially form heterodimers rather than homodimers. 
Many research groups have adopted different strategies to generate Fc heterodimers, 
with the goal of high heterodimerization yield, while retaining biophysical and biological 
properties of the wild-type Fc. Based on their ability to enforce heterodimerization 
between the two different HCs, the established Fc heterodimers have been extensively 
exploited as a scaffold to generate bispecific antibodies (bsAbs) in full-length IgG and 
IgG-like formats. These have many of the favorable properties of natural IgG anti-
bodies, such as high stability, long serum half-life, low immunogenicity, and immune 
effector functions. As of July 2016, more than seven heterodimeric Fc-based IgG-
format bsAbs are being evaluated in clinical trials. In addition to bsAbs, heterodimeric 
Fc technology is very promising for the generation of Fc-fused proteins and peptides, 
as well as cytokines (immunocytokines), which can present the fusion partners in the 
natural monomeric or heterodimeric form rather than the artificial homodimeric form 
with wild-type Fc. Here, we present relevant concepts and strategies for the genera-
tion of heterodimeric Fc proteins, and their application in the development of bsAbs 
in diverse formats for optimal biological activity. In addition, we describe wild-type 
Fc-fused monomeric and heterodimeric proteins, along with the difficulties associated 
with their preparations, and discuss the use of heterodimeric Fc as an alternative 
scaffold of wild-type Fc for naturally monomeric or heterodimeric proteins, to create 
Fc-fusion proteins with novel therapeutic modality.
Keywords: bispecific antibody, Fc engineering, heterodimeric Fc, Fc-fusion proteins, immunocytokines, antibody 
engineering
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iNTRODUCTiON
Bispecific antibodies (bsAbs) simultaneously bind two different 
antigens or two distinct epitopes on the same antigen as a single 
molecule; they differ from naturally occurring immunoglobulin 
G (IgG) monospecific antibodies (mAbs) (1, 2). Owing to 
their additional targeting ability, bsAbs often offer improved 
clinical benefits for the treatment of complicated diseases, 
such as cancers and immune disorders, wherein multiple 
cell-surface receptors or ligands are engaged (1–3). Numerous 
efforts have been made to engineer mAbs into bsAbs, which 
has resulted in the generation of more than 60 different bsAb 
formats (3–5). Many bsAbs have been engineered by linking 
antibody fragments, such as single-chain variable fragments 
(scFv), antigen-binding fragments (Fab), and heavy (VH) and 
light chain (VL) variable domains, as well as their appendages 
to IgG-format mAbs (3–6). However, these novel formats, 
deviating from the conventional IgG structure, often suffer 
from poor physicochemical properties, such as low solubility 
and aggregation, difficulties in large-scale manufacturing, poor 
pharmacokinetics, and potential immunogenicity (3–6). To 
improve the developability, bsAbs in the formats of intact IgG or 
IgG-like (containing an Fc) architectures have been extensively 
developed (5–7).
Conventional IgG antibodies are bivalent and monospecific, 
the assembly of which depends upon in  vivo homodimeriza-
tion of two identical heavy chains (HCs), which is mediated by 
homodimeric associations between CH3 domains, and subse-
quently disulfide linkages between each HC and each light chain 
(LC), in B cells (8–11). Thus, the development of bsAbs, using 
intact IgG formats with wild-type HCs and LCs, faces HC–HC 
and HCVH-CH1–LC mispairing problems (5, 7). Some approaches 
for IgG-based bsAbs, based on wild-type homodimeric Fc 
regions, have been utilized, such as a dual-action Fab (DAF, 
two-in-one antibody) (12), a κλ-body (13), and a rat/mouse 
chimeric antibody (14). However, DAF and κλ-body technolo-
gies require extensive antibody engineering and screening and 
are not easy to generate with previously established mAbs. The 
rat/mouse chimeric antibody requires multiple purification 
stages, suffers from low purification yields, and faces potential 
immunogenicity.
To address the HC mispairing problem, heterodimeric Fc 
technology, which enables two different HCs to be prefer-
entially assembled together, rather than with the same HCs, 
has been developed (5, 7, 15). Heterodimeric, Fc-based, intact 
IgG-format bsAbs have been developed in combination with 
a common LC approach (16) or with two distinct LCs, using 
the CrossMab technology (17) and ortho-Fab IgG technol-
ogy (18). Additional heterodimeric Fc scaffolds have been 
extensively exploited for the generation IgG-like bsAbs by 
appending antigen-binding antibody fragments, such as VH, 
VL, scFv, Fab, and single-chain Fab (scFab). Depending on the 
designed architectures, the resulting bsAbs differ in antigen 
specificity (from monospecific to tetraspecific) and antigen-
binding valency (from monovalent to tetravalent). In addition 
to the heterodimeric IgG scaffolds for bsAbs, heterodimeric 
Fc fragments are now emerging as excellent scaffolds to create 
Fc-fused monomeric or heterodimeric proteins or cytokines, 
which are challengeable formats to be achieved by wild-type 
homodimeric Fc.
In this review, we first focus on the design and generation 
of heterodimeric Fc and their application in the development 
of therapeutic bsAbs in diverse formats. We then describe the 
current status of homodimeric Fc-fused monomeric proteins 
and peptides and propose that heterodimeric Fc fragments, 
which can present the fusion partner as native-like monomeric 
or heterodimeric forms, represent a promising scaffold for the 
next generation of Fc-fused proteins and cytokines.
HeTeRODiMeRiC Fc eNGiNeeRiNG
Wild-type Fc homodimerization is initially mediated by a 
large, tightly packed interface (~2469  Å2 buried surface area), 
between the two identical CH3 domains with sub-nanomolar 
affinity, and subsequently by disulfide linkages in the hinge 
region (Figure  1A) (8, 9). For this reason, heterodimeric Fc 
variants have been mainly engineered through the replacement 
of homodimer-favoring interactions at the CH3 domain interface 
with heterodimer-favoring interactions. This is achieved by 
introducing asymmetric mutations in each CH3 domain, which 
promotes the assembly of HCs from two different antibodies 
(Figure  1B). This heterodimeric Fc engineering, using CH3 
variant pairs, has been approached using two strategies: (1) 
structure-based rational design and (2) directed evolution.
X-ray crystal structures of human IgG1 Fc show that Fc 
homodimerization is driven by both hydrophobic interactions at 
the center of the CH3 interface core and symmetric electrostatic 
interactions surrounding the rim of the hydrophobic core (19, 
20), as schematically shown in Figure 2A. Thus, structure-based 
rational design of heterodimeric Fc fragments has been utilized 
to generate heterodimeric CH3 variant pairs (CH3A:CH3B) 
with different mutations in each chain at the CH3 interface core 
such that the variant pair thermodynamically favors the forma-
tion of heterodimers over the homodimers. The structure-based 
rational design of such heterodimeric CH3 variant pairs can 
be classified into four strategies: (i) symmetric-to-asymmetric 
steric complementarity design (e.g., KiH, HA-TF, and ZW1) 
(21–24), (ii) charge-to-charge swap (e.g., DD-KK) (25), (iii) 
charge-to-steric complementarity swap plus additional long-
range electrostatic interactions (e.g., EW-RVT) (26), and 
(iv) isotype strand swap [e.g., strand-exchange engineered 
domain (SEED)] (7, 24), as summarized in Table  1. Critical 
parameters in heterodimeric Fc engineering include the yield 
of heterodimeric Fc formation over unwanted homodimeric Fc 
contaminants, minimal loss in stability relative to the natural 
Fc, and maintaining natural Fc-like properties, such as serum 
half-lives and effector functions. Heterodimeric Fc-directed 
bsAb formation usually yields greater than 90% of the desired 
product by co-expressing two heterodimer Fc-based antibodies. 
This makes it feasible for large-scale production and quality 
control to meet clinical needs. In contrast to heterodimeric 
Fc engineering, an approach to generate monomeric Fc frag-
ments was explored by introducing four mutations at the CH3 
interface (27).
FiGURe 1 | Schematic diagram showing the assembly of conventional igG and heterodimeric Fc-based igG-format bsAbs. (A) The homodimeric 
interactions between the wild-type CH3 domains are the initial driving force for HC homodimerization and subsequently disulfide bonds in the hinge regions and 
between the HC and LC complete the assembly of conventional IgGs, which are bivalent and monospecific. (B) Heterodimer Fc technology introduces asymmetric 
mutations in each CH3 domain, which enforces two different HCs to be predominantly assembled together, while disfavoring homodimerization between the same 
HCs. Heterodimeric Fc fragments facilitate the generation of IgG-format bsAbs, which can simultaneously bind to two different antigens.
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Symmetric-to-Asymmetric Steric 
Complementarity Design
In a pioneering approach, Carter and colleagues from Genentech 
conceived the heterodimeric Fc variant and invented the so-called 
“Knobs-into-Holes (KiH)” Fc technology (21, 22). The concept 
was to introduce a “knob” in one CH3 domain (CH3A) by sub-
stitution of a small residue with a bulky one (i.e., T366WCH3A in 
EU numbering). To accommodate the “knob,” a complementary 
“hole” surface was created on the other CH3 domain (CH3B) 
by replacing the closest neighboring residues to the knob with 
smaller ones (i.e., T366S/L368A/Y407VCH3B) (Figure  2B) (15). 
The “hole” mutation was optimized by structured-guided 
phage library screening (21). X-ray crystal structures of KiH Fc 
variants (28, 33) demonstrated that heterodimerization is ther-
modynamically favored by hydrophobic interactions driven by 
steric complementarity at the inter-CH3 domain core interface, 
whereas the knob–knob and the hole–hole interfaces do not favor 
homodimerization owing to steric hindrance and disruption of 
the favorable interactions, respectively. The KiH Fc was further 
engineered to improve purity and stability by introducing an 
additional inter-CH3 domain disulfide bond pair, S354CCH3A–
Y349CCH3B, generating the KiHS-S Fc variant. This exhibited a 
high yield of heterodimerization (~95%) and improved thermal 
melting (Tm) of the CH3 domain by 6 to ~78°C (16). Most KiH 
Fc-based bsAbs currently being evaluated in clinical trials have 
adopted the KiHS-S Fc as a scaffold (Table 2).
Extensive strategies combining structure-based computa-
tional design of many variants and subsequent experimental 
validation to assess the heterodimerization yield have been 
adopted to generate other heterodimeric Fc variants with steri-
cally complementary mutations. These include HA-TF Fc from 
Xencor (23) and ZW1 Fc from Zymeworks (24). Particularly, 
ZW1 was generated by a two-stage approach, combining nega-
tive design to first destabilize the natural Fc homodimer-favoring 
interactions at the CH3–CH3 interfaces and then positive design 
of the previously designed variant to increase biophysical stability 
(24, 45). Negative design, maximizing unfavorable interactions 
in potential homodimers while promoting specificity between 
heterodimeric species, generated an Fc variant with F405A/
Y407VCH3A–T366L/T394WCH3B, and resulting in a heterodimeri-
zation yield of ~95% (24). However, the Tm of the CH3 domain 
was ~72°C, similar to that of KiH Fc (22), but ~10°C lower than 
that of the wild-type CH3 domain (30). The subsequent positive 
design, which added T350V/L351YCH3A–T350V/K392LCH3B muta-
tions to the first variant, yielded ZW1 (T350V/L351Y/F405A/
Y407VCH3A–T350V/T366L/K392L/T394WCH3B), which retained 
the high Fc heterodimerization yield of ~95% and exhibited 
Fc stability similar to that of the wild-type CH3 domain with a 
Tm value of 81.5°C (24). The high heterodimer purity of ZW1, 
validated by stable expression in Chinese hamster ovary (CHO) 
cells, and the favorable biophysical properties could improve the 
manufacturability of ZW1-based bsAbs (45).
More recently, Leaver-Fay et  al. (29) computationally pro-
duced heterodimeric Fc variants, using an explicit multistate 
design (sequence optimization) combined with negative design 
to destabilize and eliminate homodimer-favoring inter-CH3 
interactions. One of the best clones, 7.8.60 Fc, was first designed 
by introducing mutations of D399MCH3A–K409VCH3B to elimi-
nate the conserved electrostatic interactions of D399-K392/
K409 in the wild-type CH3 interface. In the next-round, 
computational optimization identified the following substitu-
tions sequentially: Y407ACH3A–T366VCH3B to minimize CH3B 
FiGURe 2 | Schematics of the major interactions contributing to homodimeric CH3 interactions in the wild-type (A) and heterodimeric CH3A–CH3B 
interactions in the KiH (B), DD-KK (C), and ew-RvT (D) heterodimeric Fc variants. In (A), due to the twofold symmetry of the inter-CH3 interface, each 
pairwise interaction is represented twice in the structure. In (B–D), the upper panels highlight the main heterodimeric Fc-driving interactions with the indicated color 
codes. The lower panels show the crystal structures of the wild-type Fc [PDB 3AVE (19)] and the representative heterodimeric Fc variants of KiH [PDB 4NQS (28)], 
DD-KK [PDB 5DK2 (29)], and EW-RVT [PDB 4X98 (30)], highlighting the inter-CH3 domain interfaces. The images were generated using PyMol software (DeLano 
Scientific LLC).
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homodimerization and to improve the heterodimer formation, 
K360DCH3A − Q347RCH3B to eliminate CH3B homodimers, and 
finally E345RCH3B to strengthen the K360DCH3A−Q347RCH3B 
interaction (Table 1). The crystal structure determined clearly 
resolved the interface and showed that the models were very 
accurate. The 7.8.60 heterodimeric Fc combined with orthogo-
nal Fab interface mutation technology (18) produced intact 
IgG-format bsAbs with ~93% purity (29).
Charge-to-Charge Swap Design
As an alternative approach, Gunasekaran et al. from Amgen (25) 
sought to design a heterodimeric Fc by reversing symmetric charge 
complementarity at the CH3 domain interface, while retain-
ing hydrophobic core integrity (Figure  2C). Owing to twofold 
symmetry at the inter-CH3 interface, the targeted electrostatic 
interaction pairs were symmetrically duplicated on both periph-
eral sides of the hydrophobic core (Figure 2A). They converted 
the symmetric charge-pair residues into asymmetric charge 
polarity by first designing a K409DCH3A–D399KCH3B pair variant 
and then further screening for additional charge-pair mutations 
through experimentally assessing heterodimerization yield. This 
resulted in DD-KK with K409D/K392DCH3A–D399K/E356KCH3B 
mutation pairs. The asymmetric charge mutation pairs drove 
heterodimerization, whereas “positively charged” and “negatively 
charged” homodimers were suppressed by unfavorable repulsive 
charge interactions. Particularly, E356KCH3B was introduced in 
an attempt to suppress the FcCH3B–FcCH3B homodimerization to 
increase the purity of FcCH3A–FcCH3B heterodimer. The DD-KK 
design resulted in greater than 90% heterodimerization depend-
ing on the transfection ratio of the two chains.
Charge-to-Steric Complementarity 
Swap and Long-Range electrostatic 
interaction Design
The concept of KiH and DD-KK Fc design can be summarized as 
the replacement of the symmetric hydrophobic and electrostatic 
TABLe 2 | Heterodimeric Fc-based antibody formats, generated in previous studies, and now being evaluated in clinical trials.
Antibody format Heterodimeric  
Fc scaffold
Fusion format (target) Clinical trials Reference
FcCH3A FcCH3B
Monospecific and monovalent antibodies
VH-Fc/VL-Fc EW-RVT VH (c-Met) VL (c-Met) – (26)
Fc/Fab-Fc KiH – Fab (c-Met) Phase 3 (failed) (34)
HCVH-CH1-Fc/LC-Fc DD-KK HCVH-CH1 (mTNFR1) LC (mTNFR1) – (25)
igG-like formats with appendages of scFv and scFab
scFv-Fc/scFv-Fc EW-RVT scFv (c-Met) scFv (VEGFR-2) – (26)
scFv-Fc/scFv-Fc DD-KK scFv (CD3) scFv (TARTK) – (25)
Fc/scFv2-Fc (Fc/BiTE-Fc) KiH – scFv2 (CD3/EpCAM) – (35)
Fab-Fc/scFv-Fc HA-TF Fab (CD123) scFv (CD3) Phase 1 (36)
Fab (CD20) scFv (CD3) Phase 1
Fab-Fc/scFab-Fc (OAscFab-IgG) KiHS-S Fab (EGFR) scFab (IGF-1R) – (37)
scFab-Fc/scFab-Fc-scFv KiHS-S scFab-Fc (EGFR) scFab-Fc-scFv (IGF1R/HER3) – (38)
scFab-Fc-scFv /scFab-Fc-scFv KiHS-S scFab-Fc-scFv (EGFR/HER3) scFab-Fc-scFv (IGF1R/HER3) – (38)
Fab-CrossMabCH1-CL IgG KiHS-S Fab (CEA) Fab-CrossFabCH1-CL (CEA/CD3) Phase 1 (39, 40)
Fv-/Fv-CrossMabCH1-CL IgG KiHS-S Fv-Fab-Fc (HER3/VEGF) Fv-CrossFabCH1-CL-Fc (HER2/EGFR) – (41)
intact igG formats with correct LC association
Common LC-IgG KiHS-S Fab (FIXa) Fab (FX) Phase 3 (42)
CrossMabCH1-CL IgG KiHS-S Fab (Ang-2) CrossFabCH1-CL (VEGFA) Phase 1 (RG7221);  
Phase 2 (RG7716)
(17, 39)
Four-in-one CrossMabCH1-CL IgG KiHS-S Dual-action Fab (EGFR/HER3) Dual-action CrossFabCH1-CL (HER2/VEGF) – (41)
Ortho-Fab IgG DD-KK Ortho-Fab (EGFR) Ortho-Fab (c-Met) Phase 1 (18)
intact igG formats with in vitro assembly
IgG KiH Fab (BACE1) Fab (TfR) – (43, 44)
TABLe 1 | Design and strategies for heterodimeric Fc variants.
Heterodimeric 
Fc name
Paired mutations Heterodimer-favoring interactions PDB iD Reference
CH3A chain CH3B chain
KiH T366W T366S/L368A/Y407V Hydrophobic/steric complementarity 4NQS/5DI8/5HY9 (28)
KiHS-S T366W/S354C T366S/L368A/Y407V/Y349C KiH + inter-CH3 domain S-S bond – (16, 29)
HA-TF S364H/F405A Y349T/T394F Hydrophobic/steric complementarity – (23)
ZW1 T350V/L351Y/F405A/
Y407V
T350V/T366L/K392L/T394W Hydrophobic/steric complementarity 4BSW (24)
7.8.60 K360D/D399M/Y407A E345R/Q347R/T366V/K409V Hydrophobic/steric complementarity + 
electrostatic complementarity
5DJZ (Partial) (29)
DD-KK K409D/K392D D399K/E356K Electrostatic complementarity 5DK2 (25)
EW-RVT K360E/K409W Q347R/D399V/F405T Hydrophobic/steric complementarity plus  
long-range electrostatic interaction
4X98 (26, 30)
EW-RVTS-S K360E/K409W/Y349C Q347R/D399V/F405T/S354C EW-RVT + inter-CH3 domain S-S bond 4X99 (30)
SEED IgA-derived 45 residues  
on IgG1 CH3
IgG1-derived 57 residues  
on IgA CH3
Hydrophobic/steric complementarity  
(strand exchange between IgG and IgA)
– (31)
A107 K370E/K409W E357N/D399V/F405T Hydrophobic/steric complementarity +  
hydrogen bonding complementarity 
(directed evolution using yeast surface display)
– (32)
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interactions conserved at the CH3 interface with the same, but 
asymmetric, interactions. In contrast to the sterics-based KiH 
design and charge-swap DD-KK design, Choi et al. (26) replaced 
the conserved, symmetric electrostatic interactions at the buried 
interface of the CH3 domains with asymmetric hydrophobic 
interactions. This resulted in the generation of a W-VT Fc vari-
ant with K409WCH3A–D399V/F405TCH3B mutations, favoring Fc 
heterodimer formation (~77% purity) due to complementary 
hydrophobic interactions, while disfavoring homodimers owing 
to the loss of the K409–D399 electrostatic interactions and the 
steric collision of K409WCH3A–F405CH3A. To increase the heter-
odimerization yield of W-VT, they replaced a K360–Q347 pair 
with negligible interactions, owing to the long distance (4.61 Å) at 
the rim of the CH3 interface (19) with the K360ECH3A–Q347RCH3B 
asymmetric mutation pair, which favors the heterodimer 
because of the long-range electrostatic  interaction at a distance 
of 3.45 Å (30). The combined heterodimeric Fc, called EW-RVT 
(Figure  2D), showed a heterodimer yield of ~91% and a CH3 
domain Tm value of ~77.5°C, which were comparable to those 
of KiH and DD-KK Fc variants (26). The X-ray crystal structure 
6Ha et al. Heterodimeric Fc Technology and Its Applications
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of the EW-RVT Fc heterodimer led to the addition of an inter-
CH3 disulfide bond with a Y349CCH3A–S354CCH3B pair, yielding 
EW-RVTS-S Fc. The asymmetric disulfide bond was confirmed 
by resolving the crystal structure (30). EW-RVTS-S Fc showed 
improved heterodimer yield (by ~3%) and higher thermody-
namic stability of the CH3 domain (by ~2.8°C) compared to 
those parameters of the parent EW-RVT Fc (30). The crystal 
structures of EW-RVT and EW-RVTS-S Fc fragments, obtained 
to determine the molecular details of the CH3A/CH3B interface, 
revealed that the mutations did not cause any significant changes 
in the Fc structure (30). In agreement with the crystal structure, 
the EW-RVT Fc heterodimer displayed the native IgG1-like, pH-
dependent, neonatal Fc receptor (FcRn) binding pattern, and Fcγ 
receptor (FcγR) interaction, which were equivalent to those of 
the native IgG1 (previously reported) (46, 47). This suggests that 
the EW-RVT-based antibody will have similar serum half-lives 
and effector functions to those of the conventional human IgG1.
isotype Strand Swap Design
Davis et  al. from Merck Serono (31) designed a heterodimeric 
Fc by mixing human IgG and IgA CH3 domain segments to 
create a complementary CH3 heterodimer, which was referred 
to as SEED Fc. Native CH3 domains of human IgA and IgG are 
structurally similar (10), but cannot dimerize because of lower 
homology within interface residues. They analyzed the structural 
dimerization motif in the CH3 domain of each isotype and 
devised SEED through the exchange of some β-strand segments 
in the CH3 domain of each isotype to drive heterodimer forma-
tion through steric complementary contact surfaces. The SEED-
based antibodies (e.g., SEEDbody) were purified with a protein 
A resin and exhibited long serum half-life and effector functions 
comparable to those of wild-type human IgG1 Fc-based antibod-
ies (48). However, owing to the artificial sequence of the SEED 
CH3 heterodimer, the potential immunogenicity has not been 
determined.
Directed evolution of Heterodimeric Fc
Aforementioned Fc heterodimers have been generated through 
structure-based rational design or computational modeling. 
Recently, Choi et al. (32) generated heterodimeric Fc variants 
through directed evolution combined with yeast surface display 
and high-throughput screening (49, 50). A combinatorial het-
erodimeric Fc library display system was developed by mating 
two haploid yeast cell lines; one haploid cell line displayed an 
Fc chain library (displayed FcCH3A) with mutations in one CH3 
domain on the yeast cell surface, and the other cell line secreted 
an Fc chain library (secreted FcCH3B) with mutations in the other 
CH3 domain. In the mated cells, secreted FcCH3B was displayed 
on the cell surface through heterodimerization with the dis-
played FcCH3A. Fluorescence-based detection of this interaction 
enabled screening of the library for heterodimeric Fc variants 
by flow cytometry. For the proof-of-concept, they constructed 
combinatorial heterodimeric Fc libraries with simultaneous 
mutations on targeted residues of both CH3A and CH3B based 
on the template of the W-VT Fc variant, and screened the 
libraries to isolate numerous heterodimeric Fc variants with 
heterodimerization yields of ~90%. This directed evolution 
approach identified unexpected heterodimer-favoring muta-
tion pairs at the CH3 interface, such as hydrogen bonding or 
cation–π interactions, as well as homodimer-disfavoring pairs, 
which have not been tested by structure-guided rational design. 
The best clone, A107, exhibited a heterodimerization yield of 
~93%, which was much higher than that (~77%) of the parent 
W-VT Fc variant.
HeTeRODiMeRiC Fc-BASeD ANTiBODieS 
iN DiveRSe FORMATS
Heterodimeric Fc are compatible with independent fusion of two 
different antigen-binding units to the N- and/or C-terminus of 
each Fc chain. This facilitates the creation of diverse heterodi-
meric Fc-based antibodies with differences in specificity, binding 
valency, geometry of target-binding sites, among others, as sum-
marized in Figure 3 and Table 2.
Monospecific and Monovalent Antibodies
Heterodimeric Fc-based monospecific antibodies (mAbs) with 
monovalent antigen binding have been generated by fusion of 
the Fab to the N-terminus of only one Fc chain (Fc/Fab-Fc), the 
scFv to the N-terminus of only one Fc chain (Fc/scFv-Fc), the 
VH-CH1 (HCVH-CH1) and VL-CL to the respective N-termini of 
each heterodimeric Fc chain (HCVH-CH1-Fc/LC-Fc), or the VH and 
VL to the respective N-termini of each heterodimeric Fc chain 
(VH-Fc/VL-Fc) (Figure 3).
The Y-shape of typical IgG antibodies often limits their utility 
against some targets, whereby bivalent target-binding dimerizes 
and agonizes, rather than antagonizes, the intended targets. 
For example, targeting the c-Met receptor tyrosine kinase with 
bivalent antibodies can mimic the ligand hepatocyte growth 
factor (HGF)-mediated agonism via receptor dimerization (51). 
To address this issue, Genentech developed a KiH Fc-based, one-
armed Fc/Fab-Fc format monovalent antibody, onartuzumab 
(MetMab), through fusion of a humanized anti-c-Met 5D5 
Fab to the N-terminus of only the “hole” of the Fc chain (34). 
Whereas the bivalent anti-c-Met 5D5 IgG antibody acted as an 
agonist causing c-Met-activated tumor cell growth, rather than 
growth inhibition, the monovalent MetMab bound the recep-
tor in a one-to-one fashion to inhibit HGF binding and block 
receptor activation, thus acting as an antagonist. Co-expression 
of three chains, specifically the Fc, HCVH-CH1-Fc, and LC, from 
three respective cistrons on a single plasmid, and targeting these 
chains to the periplasmic space of Escherichia coli, efficiently 
resulted in the production of MetMab. Purification by size-
exclusion chromatography yielded ~95% purity (34). A clinical 
trial of MetMab combined with the epidermal growth factor 
receptor (EGFR) kinase inhibitor erlotinib to block metastasis 
in non-small cell lung cancer was recently halted in Phase 3, but 
other clinical trials with MetMab are expected. The EW-RVT Fc 
variant was also applied to make a MetMAb-like monovalent 
antibody in the VH-Fc/VL-Fc format, called msMet, wherein 
the VH and VL of MetMab were fused to the N-terminus of 
each heterodimeric Fc chain (26). As a single agent, the msMet 
antibody suppressed the in vivo tumor growth of human gastric 
cancer xenografts in mice.
FiGURe 3 | Overview of heterodimeric Fc-based antibodies, which are subdivided into three classes: (A) monospecific and monovalent antibodies, 
(B) igG-like formats with appendages of scFv and scFab, and (C) intact igG formats with correct LC association. Each domain is color coded as 
indicated in the dotted box. Connecting peptide linkers in scFv and scFab fragments are shown by thin black lines. Details are described in the text.
7
Ha et al. Heterodimeric Fc Technology and Its Applications
Frontiers in Immunology | www.frontiersin.org October 2016 | Volume 7 | Article 394
DD-KK Fc was exploited to generate a monovalent 14D2 
antibody, in the HCVH-CH1-Fc/LC-Fc format, to target tumor 
necrosis factor receptor 1 (TNFR1) by linking the VH-CH1 and 
VL-CL of the anti-TNFR1 14D2 antibody to the N-terminus 
of each heterodimeric Fc chain (25). The parent bivalent 14D2 
antibody showed undesirable activity, specifically activation of 
TNFR1 at low doses via cross-linking of the receptor, similar to 
that observed for the TNF ligand. However, the monovalent anti-
body was devoid of agonistic activity, and blocked TNF-mediated 
chemokine induction in mice. Importantly, the monovalent 14D2 
antibody exhibited similar pharmacokinetic profiles as the full-
length IgG when injected in mice.
igG-Like Formats with Appendages 
of scFv and scFab
Heterodimeric Fc technology can resolve the HC mispairing 
problem, but still faces the challenge of a LC-pairing problem, 
specifically, cognate HCVH-CH1-LC pairing in the Fab region, 
to generate bsAbs in intact IgG formats (5, 7). To address the 
HCVH-CH1-LC-pairing problem, single-chain antigen-binding 
units, such as scFv and scFab, have been, respectively, linked to 
each heterodimeric Fc chain or tandemly linked to one hetero-
dimeric Fc chain, generating IgG-like bsAbs in formats of 
scFv-Fc/scFv-Fc, scFab-Fc/scFab-Fc, Fc/scFv2-Fc, Fab-Fc-VH/
Fab-Fc-VL, Fab-Fc/scFv-Fc, Fab-Fc/scFab-Fc, and scFab-Fc-
(scFv)/scFab-Fc-scFv (Figure 3).
The EW-RVT Fc was exploited to generate a bsAb, dubbed 
bsVeMet, simultaneously targeting both c-Met and VEGF recep-
tor 2 (VEGFR-2), with two respective antigen-specific scFvs fused 
to the N-termini of each heterodimeric Fc in the format of scFv-
Fc/scFv-Fc (26). The bsVeMet more potently inhibited HGF and 
VEGF-stimulated cell proliferation, downstream signaling, and 
in vivo angiogenesis than the two parent mAbs.
Furthermore, bsAbs have been extensively designed to recruit 
immune effector cells, such as T cells, to tumor cells (52, 53). 
Bispecific T-cell Engager (BiTE) was constructed by tandem 
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connection of two scFvs, one of which was specific to CD3 on 
T cells and the other was specific to a tumor-associated antigen 
on tumor cell surfaces. The goal of this strategy was to engage 
cytotoxic T cells for lysis of the targeted antigen-expressing 
cancer cells, and was first developed by Mack and colleagues 
(54). Later, the CD19 × CD3 BiTE blinatumomab was developed 
by Micromet and clinically approved in 2014 for the treatment 
of relapsed/refractory B-cell acute lymphocytic leukemia (55). 
However, the serum half-life of tandem scFv-based BiTEs in 
mice was only 5–6 h (56), which was much shorter than that of 
Fc-containing antibodies. The fast clearance of blinatumomab 
requires infusions or repeated injections to maintain a thera-
peutically effective dose over a prolonged period, specifically, 
daily infusions for 8  weeks in clinical trials (57). To improve 
pharmacokinetics of such scFv-based BiTEs, a DD-KK Fc-based 
bsAb was generated in the scFv-Fc/scFv-Fc format by fusing two 
scFvs with different binding specificities, one against human CD3 
and the other against a tumor-associated receptor tyrosine kinase 
(TARTK), to each Fc heterodimer chain (25). Due to the presence 
of the Fc region, the scFv-Fc/scFv-Fc antibody exhibited a much 
longer in vivo half-life in mice and could be administered more 
infrequently compared to other types of CD3 bispecific scFv 
fragments (25). The CD3 × TARTK bsAb completely suppressed 
the growth of the TARTK-positive glioma in a xenograft mouse 
model.
Xu et al. from Sutro Biopharma (35) produced a KiH Fc-based 
BiTE bsAbs using the E. coli-based cell-free expression system. 
They designed epithelial cell adhesion molecule (EpCAM) × CD3 
bsAbs in the two-armed scFv-Fc/scFv-Fc format or the one-
armed Fc/scFv2-Fc (i.e., Fc/BiTE-Fc) format and further reversed 
the two formats by exchanging the “knob” Fc and “hole” Fc fusion 
partner. They found that the expression yield and biological 
activities, such as dual targeting and tumor cell killing by engag-
ing T cells, was highly variable and depended on the formats. 
This suggested that a more sophisticated optimization process is 
necessary to determine the optimal ratio of the two expression 
plasmids for enhanced cell-free expression of the Fc fusion part-
ner for the two scFvs or the tandem scFv BiTE. Intriguingly, the 
KiH Fc-based bsAb (100 kDa) showed significantly longer serum 
half-life (T1/2 ≈  4.9–5.2  days) than the BiTE control (50  kDa) 
(T1/2  ≈  0.2  days), but were less stable than trastuzumab IgG 
(150 kDa) (T1/2 ≈ 25 days) and scFv-Fc (100 kDa) (T1/2 ≈ 9.1 days) 
in mice. This might be attributed to destabilizing mutations in the 
CH3 domains of the KiH Fc (35).
Using an HA-TF Fc scaffold, Xencor generated Her2 × CD3 
or Her2 × CD16 bsAbs in Fab-Fc-VH/Fab-Fc-VL (dubbed mAb-
Fv) format through the fusion of VH and VL domains of CD3 or 
CD16 antibodies to the C-termini of two distinct HCs (23). The 
advantage of the mAb-Fv format is improved tumor targeting due 
to bivalent antigen engagement through two intact arms of the 
IgG mAb, compared to the monovalent target-binding formats, 
such as scFv-Fc/scFv-Fc and scFab-Fc/scFab-Fc. However, mAb-
Fv showed non-native oligomeric species and the C-terminal Fv 
exhibited inferior affinity to the CD16 or CD3 antigen compared 
to the parent Fab. This was most likely due to steric hindrance 
and suggested the need for C-terminal-fused Fv optimization. 
For these reasons, Xencor adopted an HA-TF Fc-based Fab-Fc/
scFv-Fc bsAb format (dubbed “plug-and-play” platform), 
which showed native mAb-like stability and non-compromised 
antigen-binding activity (36). For example, the Fab-Fc/scFv-Fc 
formatted bsAbs, such as CD123  ×  CD3 (XmAb14045) and 
CD20 × CD3 (XmAb13676), are expected to begin clinical Phase 
1 trials for acute myeloid leukemia (NCT02730312) and B-cell 
malignancies, respectively, in 2016.1 Glenmark Pharm is also 
developing bsAbs in a heterodimeric Fc-based Fab-Fc/scFv-Fc 
format (dubbed “BEAT” by Glenmark), in which the heterodi-
meric Fc was designed by introducing mutations, mimicking the 
natural association of the heterodimeric T-cell receptor (TCR) α 
and β chains, into the interface between the two CH3 domains 
of IgG (58).
Schanzer et al. from Roche (37, 59) generated a KiH Fc-based 
bsAb XGFR in the format of Fab-Fc/scFab-Fc for targeting EGFR 
with the Fab format in one arm and the insulin-like growth factor 
receptor type I (IGF-1R) with scFab format in the other arm. The 
format of XGFR bsAb, the so-called one arm scFab IgG (OAscFab-
IgG) was devised to prevent incorrect pairing of LCs, while 
maintaining the closest possible format to intact IgG. XGFR was 
produced with high expression yields comparable to those of the 
respective parent IgG mAbs. However, other tested bsAb formats 
of IgG-scFv (IGF-1R IgG with C-terminal attachment of disulfide-
stabilized EGFR scFv) and dual-variable domain (DVD)-IgG 
(IGF-1R IgG with the N-terminal attachment of EGFR VH and 
VL in the HC and LC, respectively) showed ~2-fold and ~16-fold 
lower expression yields than that of the OAscFab-IgG format (37, 
59). To further increase immune effector functions triggered by 
XGFR bsAb, the heterodimeric Fc portion was glycoengineered 
to remove the fucosylation, leading to strong antibody-dependent 
cell-mediated cytotoxicity. The resulting XGFR demonstrated 
potent anti-tumor efficacy in multiple mouse xenograft tumor 
models (37, 59). In addition, Castoldi et  al. from Roche (38) 
constructed a KiHS-S Fc-based trispecific antibody (dubbed 
TriMAb) in the scFab-Fc-(scFv)/scFab-Fc-scFv format, in which 
anti-EGFR and anti-IGF-1R scFabs are on the respective arm of 
IgG with anti-Her3 scFv to fused to the C-terminus of both chains 
or only one chain. The EGFR × IGF-1R × HER3 TriMAb showed 
growth inhibitory effects comparable to that of a combination of 
each single parental antibody, in a model cell proliferation assay.
intact igG Formats with Correct 
LC Association
IgG-like bsAbs based on appending scFv and scFab to hetero-
dimeric Fc fragments have overcome HCVH-CH1-LC mispairing 
issues within the Fab region, but they are limited in their use of 
linkers, the length and composition of which often needs to be 
optimized. A sub-optimal linker can cause undesirable problems, 
such as loss of antigen binding, due to binding site hindrance, 
poor expression levels, immunogenicity, poor pharmacokinetics, 
and in  vivo cleavage. Thus, many attempts have been made to 
develop bsAbs that deviate minimally from natural IgG antibodies 
without the use of artificial linkers. Since antigen specificity usu-
ally resides in the Fv chain composed of the VH and VL, correct 
1 http://xencor.com/ 
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pairing between the cognate HC and LC during  co-expression 
and assembly of bsAbs is essential to ensure antigen-binding 
specificity and affinity. LC mispairing occurs because the Fab 
heterodimerization interfaces of VH–VL and CH1–CL between 
two distinct antibodies are almost identical, though the comple-
mentarity determining regions (CDRs) of VH and VL are quite 
different. Thus, to generate bsAbs using a full-length IgG format, 
cognate HCVH-CH1-LC pairing should be ensured, in addition 
to correct HC pairing by heterodimeric Fc technology. The LC 
mispairing problem has been addressed by using a common LC 
(15, 16), a domain crossover (CrossMab) (17), and a designed 
orthogonal Fab interface (18) (Figure 3).
The use of a common LC, compatible with the two distinct 
HCVH-CH1s, is a straightforward way to construct bsAbs with intact 
IgG formats (15). Two mAbs can be first isolated from a human 
scFv phage library sharing identical VLs and then assembled into 
a single IgG format using KiH Fc-based HC heterodimerization 
(16, 60). However, this approach constrains antibody discovery 
for two different targets with a single LC or requires novel 
antibody libraries, and is difficult to adopt when using two dif-
ferent previously established antibodies. A notable example of an 
IgG-format bsAb using a common LC in combination with a KiH 
Fc is emicizumab (ACE910) developed by Chugai, which targets 
factor IXa and factor X (FIXa × FX) (61, 62). They first generated 
various FIXa- and FX-specific mAbs by immunizing mice with 
human FIXa and FX antigens and then generated a lead chimeric 
bsAb based on the retention of biological activity and the feasibil-
ity of using only one LC (62). FIXa and FX form a complex with 
cofactor FVIII but the complex formation is deficient in hemo-
philia A patients. Standard treatment for this disease includes 
frequent injection of recombinant or plasma-derived factor VIII 
(62). Emicizumab mimics FVIII functions by allowing FIXa and 
FX to be close for the formation of the complex. This is because 
the distance between the FIXa- and FX-binding sites of FVIIIa 
is similar to that between the two antigen-binding site arms of 
the Y-shaped IgG. Emicizumab overcomes the short half-life 
(T1/2 ≈ 0.5 days) of recombinant FVIII and is expected the lower 
immunogenicity. Emicizumab is now in a Phase 3 clinical study 
in patients with hemophilia A (NCT02622321) (42).
To facilitate antibody generation with a common LC, Merus 
developed a transgenic mouse (MeMo), engineered to generate 
antibodies with a single human common LC and diverse human 
HCs (63). The MeMo technology combined with their own CH3-
domain engineered heterodimeric Fc technology allows them to 
generate intact IgG-format bsAb (dubbed Biclonics by Merus).2 
A Biclonics-based bsAb MCLA-128 targeting Her2 × Her3 is now 
being evaluated in Phase 1/2 clinical trials for patients with solid 
tumors (64).
CrossMab technology from Roche (17) is another strategy to 
solve the HCVH-CH1–LC association problem in combination with 
KiH Fc technology. This technology keeps one Fab untouched, 
whereas the VH or CH1 domain of the other Fab is switched with 
partner VL or CL domains. In the early proof-of-concept stage 
of CrossMabs, they were evaluated in three formats according to 
2 http://www.merus.nl/ 
the crossover region: (1) CrossMabFab, crossover of the complete 
VH-CH1 and VL-CL domains, (2) CrossMabVH-VL, crossover 
of only the VH and VL domains, and (3) CrossMabCH1-CL, 
crossover of only the CH1 and CL domains. Although the three 
CrossMab variants showed comparable thermal stability to that 
of the parental IgG mAbs, the CrossMabCH1-CL format showed 
only minimal unwanted side products; however, the other two 
formats produced some portion of side products (17). For this 
reason, the CrossMabCH1-CL format was predominantly used 
over the other two formats. CrossMab-based bsAbs might be 
easily derived from pre-existing antibody pairs using domain 
crossover without the need for identification of common LC and 
the Fab interface mutations, required for correct LC association 
(39). Many CrossMAbs have been generated and evaluated 
and currently four different CrossMab-based bsAbs are now 
in active Phase 1/2 clinical trials (39) (Table  1). For example, 
two versions of a VEGF ×  Ang2 CrossMabCH1-CL are currently 
being evaluated in clinical trials: (1) RG7221 (Vanucizumab), 
one VEGF × Ang2 CrossMabCH1-CL, in Phase 1 in patients with 
cancers (NCT01688206) and (2) RG7716, the other tailor-made 
VEGF × Ang2 CrossMabCH1-CL, in Phase 2 trials for patients with 
macular degeneration (NCT02484690).
The CrossMabCH1-CL format was further extended by fusion of a 
Fab to the N-terminus to generate the Fab-CrossMabCH1-CL format 
for trivalent bsAbs (Figure 3). Using this format, IgG-based T-cell 
bsAbs (TCBs) with bivalent binding to carcinoembryonic antigen 
(CEA), dubbed CEA-TCB, was developed (40). Currently, a 
Phase 1 clinical trial of CEA-TCB is ongoing (NCT02324257) for 
the treatment of CEA-expressing solid tumors (39). Furthermore, 
the genetic fusion of the two different DAFs (dual-action 
Fabs, i.e., two-in-one antibody), one EGFR ×  Her3 DAF and 
another Her2 × VEGF DAF, to the N-terminus of each arm of 
a KiH-based four-in-one CrossMabCH1-CL format generated the 
EGFR × Her3 × Her2 × VEGF targeting tetraspecific IgG-format 
antibody (41) (Figure  3). The same group also generated an 
EGFR × Her3 × Her2 × VEGF targeting tetraspecific, tetravalent 
antibody by combining the CrossMabCH1-CL and DVD-IgG tech-
nologies (65), resulting in the Fv-/Fv-CrossMabCH1-CL IgG format 
(41) (Figure 3).
An alternative approach for enforcing correct HCVH-CH1–LC 
association includes introduction of a set of mutations at the het-
erodimeric VL–CL and VH–CH1 interface (18, 66, 67), similar 
to modification of the CH3 interface for the heterodimeric Fc 
design. In an ortho-Fab IgG approach (18), structure-based 
regional design introduced complementary mutations at the 
LC and HCVH-CH1 interface in only one Fab, without any changes 
being made to the other Fab (Figure 3). Based on the ortho-Fab 
IgG format combined with heterodimeric Fc technology, the 
EGFR × c-Met bsAb (LY3164530) from Eli Lilly was generated, 
which is currently being evaluated in a Phase 1 clinical study of 
patients with advanced or metastatic cancer (NCT02221882). 
Zymeworks is also currently developing intact IgG-format bsAbs 
generated by the combination of ortho-Fab IgG and ZW1 Fc 
technologies.3
3 http://www.zymeworks.com/ 
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In Vitro Assembly of intact igG Formats
Heterodimeric Fc technology alone, without the combination 
of HCVH-CH1–LC association technology, can generate intact 
IgG-format bsAbs by separate expression of two parental 
half-antibodies [HC–LC (HL) pairs] and subsequent in  vitro 
recombination into desirable bsAbs, the assembly of which is 
driven by heterodimer-favoring Fc interactions under controlled 
biochemical conditions (60). This approach allows the correct 
HCVH-CH1–LC association during the expression stage of the 
parental half-antibody and maintains the cognate HCVH-CH1–LC 
pairing in the next in  vitro assembly step. Spiess et  al. from 
Genentech (68) further combined the two separate processes 
into one step by co-culture of two transformed E. coli cell 
lines, each expressing a half-antibody. They demonstrated the 
robustness of the technology by producing 28 unique IgG 
bsAbs. However, this E. coli expression system was limited to 
production of non-glycosylated antibodies. Shatz et  al. (69) 
applied this technology to a mammalian expression system 
to produce glycosylated antibodies. A notable example of a 
bsAb prepared using the above manufacturing system is the 
TfR × BACE1 bsAb that targets TfR (transferrin receptor) and 
BACE1 (β-site amyloid precursor protein-cleaving enzyme) (43, 
44). In a human TfR knock-in mouse, the bsAb could cross 
the blood–brain barrier and accumulated in the mouse brain 
where it inhibited BACE1 to reduce brain Aβ production (44). 
This bsAb was validated in preclinical models, and is now on 
the path to clinical trials.
Unlike the human IgG1 isotype, IgG4 has been shown to 
undergo Fab arm exchange (FAE) both in  vivo and in  vitro, 
in which one half-antibody (HL pair) recombines with other 
half-antibodies from other IgG4 molecules (10, 70, 71). The 
structural basis of IgG4 for FAE resides in the IgG4 core hinge 
region (226Cys-Pro-Ser-Cys-Pro230), and especially the Ser228 
residue and the CH3 domains (critically, the R409 residue) 
(70, 72). To confer FAE ability to IgG1, two groups engineered 
FAE-capable IgG1 by introducing the FAE-associated IgG4-
specific mutation pairs at the core hinge region and inter-CH3 
interface, for example, D221E/P228E/L368ECH3A–D221R/P228R/
K409RCH3B (dubbed EEE-RRR) from Rinat-Pfizer (73), or only 
at the inter-CH3 interface, such as K409RCH3A–K405LCH3B 
(dubbed Duobody) from Genmab (72). The retention of the 
stable wild-type IgG1 hinge in the Duobody technology might 
be beneficial for the generation of bsAbs, which are resistant 
to reduction under physiological conditions in  vivo and are 
much more stable during storage after FAE-mediated manu-
facturing (74). It should be noted that the above two mutation 
pairs at the CH3 interface are not enough to predominantly 
produce heterodimeric Fc fragments when the two HCs are co-
expressed, unlike the KiH, DD-KK, and EW-RVT heterodimeric 
Fc technology. Instead, two mAbs based on the FAE-capable 
IgG1 are separately expressed and purified and then mixed 
together under mild redox conditions, resulting in a stable 
IgG1 bsAb with high yields (greater than 90%) (72–74). The 
EGFR ×  c-Met bsAb (JNJ-61186372) generated by Duobody 
technology was effective against EGFR inhibitor-resistant lung 
tumors in mice (75).
Fc-FUSeD PROTeiNS wiTH THe 
NATURAL MONOMeRiC OR 
HeTeRODiMeRiC FORM
The genetic fusion of proteins, such as ligand-binding soluble 
receptors, cytokines, growth factors, enzymes, and peptides, 
to the Fc domain of human IgG1 is a well-established strategy 
to extend the serum half-life and often enhance biological 
activity through dimerization of the fusion partner (76–78). 
Conjugation to the Fc may also enhance tissue penetration of 
the fusion partner by FcRn-mediated transcytosis (79, 80). In 
addition, the Fc moiety in many cases improves the biophysical 
properties of its fusion partner, such as the solubility and stabil-
ity of the protein (81). At the end of 2015, about 11 Fc-fusion 
proteins had been clinically approved (82). All of the marketed 
Fc-fusion proteins and many others in clinical trials are based 
on the wild-type human IgG1 Fc, which presents the fusion 
partner as a homodimer due to the homodimeric Fc structure. 
However, some cytokines and hormones naturally occurring in 
monomeric or heterodimeric forms exhibit markedly improved 
pharmacokinetics and even biological activities when they are 
fused to the Fc in natural forms (83). Thus, Fc-fusion, while keep-
ing the original configuration of the fusion partners, is desirable 
for those proteins. However, as described below, generation of 
such Fc-fused monomeric or heterodimeric proteins based on 
the wild-type Fc is not straightforward (Figures 4A–C) due to 
the homodimeric structure. A promising solution to this limita-
tion is the use of a heterodimeric Fc as an alternative scaffold to 
wild-type Fc (Figures 4D,E).
wild-Type Fc-Fused Protein Monomers
Naturally occurring monomeric cytokines and hormones, such 
as erythropoietin (Epo), interferon α/β (IFNα/β), and Factor IX 
(FIX), Fc-fused proteins in the native monomer format, dubbed 
Fc-fused monomers, showed improved pharmacokinetics and 
even biological activities, compared to Fc-fused dimers (83). 
Epo is a glycoprotein hormone drug of ~34 kDa that exerts its 
effects by binding to the Epo receptor to stimulate red blood cell 
production (84). Bitonti et al. (85, 86) demonstrated that human 
IgG1 Fc-fused Epo in monomeric format (Epo-Fc monomer), 
consisting of a single molecule of Epo conjugated to a wild-type 
Fc dimer (Figure 4A), exhibited enhanced pharmacokinetic and 
pharmacodynamic properties, compared to the Epo-Fc dimer, in 
both cynomolgus monkeys and humans. The inferior activity of 
the Epo-Fc dimer might be attributed to steric hindrance intro-
duced by two molecules of Epo linked to a dimeric Fc; this could 
adversely affect the binding to respective receptors (83). To pre-
pare an Epo-Fc monomer, two plasmids encoding FLAG-tagged 
Epo-Fc at the C-terminus (Epo-Fc-FLAG) and untagged Epo-Fc 
were first co-transfected into CHO cells. Three protein products 
were produced by the cells: the Epo-Fc/Epo-Fc homodimer 
(Epo-Fc dimer), the EpoFc/Epo-Fc-FLAG heterodimer (Epo-Fc 
monomer), and the Epo-Fc-FLAG/Epo-Fc-FLAG homodimer. 
The Epo-Fc monomer was purified using a combination of 
protein A chromatography, size-exclusion chromatography, and 
subsequently FLAG-affinity chromatography (85, 87).
FiGURe 4 | Fc-fused monomeric or heterodimeric proteins. (A) Wild-type Fc-based Epo-Fc dimer vs. Epo-Fc monomer. (B) Aglycosylated Fc-fused 
GLP-1/GCG monomeric peptide, generated by the LAPScovery technology. (C) Wild-type Fc-based Fc-FSH tandem homodimer vs. Fc-FSH heterodimer. 
(D) Heterodimeric Fc KiH-based IgG-fused IL2v monomer, IgG-IL2v, developed by Roche. (e) Potential use of heterodimeric Fc for the generation of Fc-fused 
monomeric or heterodimeric proteins to present the fusion partner in its naturally occurring form. The Fc-fused monomer can easily be generated by the fusion of 
monomeric protein to the N- or C-terminus of one heterodimeric Fc chain. The Fc-fused heterodimer can be generated by separate fusion of the two subunits of 
heterodimeric proteins to each chain of the heterodimeric Fc at the N- or C-terminus.
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Similar to the Epo-Fc monomer, Fc-fused monomer formats 
of IFNβ, IFNα, and FIX exhibited much better biological activ-
ity in the monkey models compared to corresponding Fc-fused 
dimers (83). Intriguingly, in the case of IFNα, the IFNα-Fc 
monomer showed very similar pharmacokinetics to that of the 
IFNα-Fc dimer; however, the IFNα-Fc monomer displayed much 
better in vivo efficacy compared to the IFNα-Fc dimer (83). This 
enhanced efficacy of IFNα-Fc monomer was also dependent 
on the length of the linker between the IFNα and Fc regions. 
Longer linker length resulted in increased specific activity of the 
IFNα-Fc monomer, indicating that there might have been some 
steric hindrance between IFNα and its receptor. The Fc-fused 
monomer was then prepared as described previously for the 
Epo-Fc monomer. Thus, the desired Fc-fused monomer could 
theoretically be prepared up to only 33% of the total expression 
yield. Despite many desirable properties of Fc-fused monomers, 
the development of wild-type Fc-based monomers faces difficul-
ties associated with isolating desired Fc-fused monomers from 
other format mixtures using robust purification steps, and is also 
limited by the inherent poor yield of a maximum of 33%.
For Fc-fused monomeric peptides, Kang et  al. from Hanmi 
Pharm (88) developed a glucagon-like peptide-1 (GLP-1)/gluca-
gon (GCG) dual agonist for the potential treatment of obesity 
and diabetes by activating both GLP-1 and GCG receptors based 
on LAPScovery™ (Long-Acting Protein/Peptide Discovery) 
technology. They chemically conjugated GLP-1/GCG peptides to 
only one arm of human IgG1 aglycosylated Fc fragments, pro-
duced from E. coli via a flexible polyethylene glycol (PEG) linker 
(Figure 4B). The GLP-1/GCG-Fc monomer exhibited markedly 
improved pharmacokinetics and greater in vivo biological activ-
ity compared to the GLP-1/GCG-Fc dimer (89). However, the 
preparation of the GLP-1/GCG-Fc monomer was complicated, 
requiring separate Fc preparation, in vitro chemical conjugation 
of the GLP-1/GCG peptide to the Fc via a PEG linker, and, finally, 
multi-step purification of the desired product from the reaction 
mixture (89). Based on LAPScovery technology, aglycosylated 
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Fc-fused monomers for insulin, human growth hormone, and 
granulocyte-colony stimulating factor were developed, and are 
now in clinical trials in Europe.4
wild-Type Fc-Fused Protein Heterodimers
For heterodimeric proteins composed of two different subunits, 
the Fc-fusion format, achieved by fusion of each subunit indepen-
dently to separate Fc fragments might be desirable to maintain 
biological activity, in comparison to the homodimeric form by 
tandem subunit linkage to wild-type Fc. Follicle-stimulating 
hormone (FSH) is a non-covalently linked heterodimeric protein 
consisting of α and β subunits, and its recombinant protein is com-
monly used for therapy in the treatment of both male and female 
infertility (90). However, it requires daily injections for several 
days for up to months due to its short half-life (35 h in humans) 
(90). To prepare long-acting FSH, Low et  al. (91) designed a 
human IgG1 Fc-fused FSH in two different formats. One is a 
single chain-linked FSH-Fc (Fc-FSH tandem homodimer) with 
tandemly linked α-β subunits fused to the N-terminus of the Fc 
fragment. The other is a heterodimeric FSH-Fc (Fc-FSH heter-
odimer) with α and β subunits fused separately to the N-termini 
of each arm of the Fc fragment (Figure  4C). They found that 
the Fc-FSH heterodimer was significantly more active than the 
Fc-FSH tandem homodimer, whereas the two Fc-fusion proteins 
had similar terminal serum half-lives in both rodents and mon-
keys. It is likely that the architecture of the Fc-FSH heterodimer 
might present the α and β subunits in a more favorable conforma-
tion for bioactivity than that of the Fc-FSH tandem homodimer. 
To purify Fc-FSH heterodimers, they inserted a 6 × His-tag into 
the C-terminus of the β subunit-fused Fc fragment only. As a 
result, whereas the Fc-FSH tandem homodimer was ~90% pure 
following a single protein A chromatography step, the Fc-FSH 
heterodimer required additional purification by nickel affinity 
chromatography to achieve similar purity. However, in addition 
to multi-step purifications, such preparations of Fc-FSH heter-
odimers gave lower purification yields (33%) compared to the 
total expression yield.
Antibody-Fused Cytokines, 
immunocytokines
Cytokines are key players in controlling immune responses dur-
ing physiological and pathophysiological processes (92). Various 
cytokines have been clinically approved for diverse immune-
related diseases, including interleukin-2 (IL2) and tumor necrosis 
factor (TNF) as well as INFα for malignant cancer therapy (92, 
93). However, the therapeutic efficacy of cytokines is often 
hampered by poor pharmacokinetics and significant toxicity 
associated with their systemic administration. To overcome such 
limitations, antibody–cytokine fusion proteins, the so-called 
immunocytokines, have been devised in an attempt to enhance 
antibody-mediated tumor tissue targeting of cytokines, and to 
increase serum half-lives (93, 94). However, a recent study in 
mice using an immunocytokine of IL2-fused to tumor antigen-
specific IgG in format of IgG-IL2, showed that the biodistribution 
4 http://www.hanmipharm.com/ 
and pharmacokinetics are entirely governed by the cytokine IL2 
moiety, rather than the expected antibody-targeting antigen 
specificity (95). The IgG-IL2 predominantly remained systemic 
and was associated with innate immune cells expressing IL2 
receptors regardless of antigen specificity or FcγR interactions, 
whereas the parent IgG antibody was preferentially accumu-
lated in antigen-targeted tumors (95). Rather than the IgG-IL2 
immunocytokine, a combination of an anti-tumor antigen IgG 
antibody and an untargeted Fc-IL2 monomer was approached for 
synergistic anti-tumor immunotherapy (96).
Furthermore, the biodistribution of immunocytokines was 
considerably influenced by the ratio of antibody to cytokine. IL12 
is a heterodimer (~70 kDa) consisting of heavy (p40) and light 
(p35) chain subunits, which are covalently linked by disulfide 
bonds (97). In an attempt to develop IL12-based immunocy-
tokines combined with an L19 scFv that targets the EDB domain 
of fibronectin, Gafner et al. (98) constructed three different forms 
of immunocytokines differing in the ratio of antibody to cytokine. 
They found that the format with 2:1 antibody to cytokine ratio of 
p40-L19 scFv/L19 scFv-p35, a heterodimeric fusion protein in 
which the disulfide-linked p35 and p40 subunits of IL12 are fused 
to L19 scFv, displayed the highest tumor-targeting performance 
in biodistribution studies. Thus, enhanced therapeutic activity 
was observed when compared to the other two formats having 
1:1 or 2:2 ratio of antibody to cytokine. Similar results were also 
obtained with IL12 immunocytokines generated with a differ-
ent F8 scFv antibody (99). With a monomeric cytokine of IL7 
(~20 kDa), the same group evaluated the biodistribution of three 
different formats of IL7-fused F8 scFv immunocytokines differ-
ing in antibody to cytokine ratios (100). They found that, as in 
the case of IL12, the format with a 2:1 antibody to cytokine ratio 
showed the highest tumor localization compared to the other two 
formats with 1:1 and 2:2 ratios.
Heterodimeric Fc-Fused immunocytokines
The above results suggest that increasing the antibody to cytokine 
ratio results in improved tumor tissue localization via decreasing 
cytokine-mediated targeting, which can potentially reduce the 
dose-related toxicity. IgG-based immunocytokines have been 
typically generated by fusion of cytokines to the C-terminus of 
homodimeric Fc fragments of HCs, which present the cytokine 
as a homodimeric form (31). However, such IgG-based immu-
nocytokines might display poor pharmacokinetics and distribu-
tion, as shown with IgG-IL2 formats (95, 101). To generate an 
IgG-based cytokine monomer format for monomeric (e.g., IL2, 
IL4, IL7, IL9, IL15, and IL21) and heterodimeric cytokines (e.g., 
IL12, IL23, IL27, and IL35), a heterodimeric Fc is an attractive 
scaffold to present cytokines with native structures. Roche 
(102, 103) generated CEA-targeted IgG-fused IL2 monomeric 
immunocytokines (CEA-IL2v) by fusion of an engineered IL2 
variant (IL2v) to the C-terminus of an antibody with the KiH 
heterodimeric Fc to obtain a 2:1 antigen-binding valence to 
cytokine ratio (Figure  4D). Similarly, they also developed the 
fibroblast activation protein (FAP)-directed IgG-IL2v mono-
meric immunocytokine (FAP-IL2v) (103, 104). Both CEA-IL2v 
(NCT02004106, NCT02350673) and FAP-IL2v (NCT02627274) 
are now being evaluated in Phase 1 clinical trials.
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CONCLUSiON AND PROSPeCTS
In summary, immunoglobulin Fc heterodimer technology is very 
useful in generation of bsAbs with various antigen specificities 
and binding valencies in full-length IgG and IgG-like formats, 
while retaining many favorable properties of natural IgG antibod-
ies. As of July 2016, more than seven heterodimeric Fc-based IgG-
format bsAbs are now being evaluated in clinical trials (Table 2). 
Nonetheless, there are some issues to be considered for heterodi-
meric Fc-based bsAbs. All of the heterodimeric Fc-based bsAbs 
require assembly with three or four separate chains, which often 
hampers cell line development for high yield expression. Since 
each heterodimeric Fc chain has different mutations in each CH3 
domain, the expression level and stability are somewhat different 
from each other, often requiring optimizing processes to identify 
the best pair between heterodimeric Fc chain and fusion partner 
(35). Furthermore, since the so far developed Fc heterodimers 
do not reach a 100% heterodimerization yield, the downstream 
process to ensure high bsAb purity, to meet clinical needs, should 
be considered from the initial stage of the heterodimeric Fc-based 
bsAb design.
In addition to bsAbs, heterodimeric Fc technology is now 
emerging as a promising scaffold for the generation of Fc-fused 
proteins and cytokines in monomeric or heterodimeric formats. 
The generation of Fc-fused monomeric proteins with wild-type 
Fc fragments is not any more desirable because it requires 
additional artificial sequences, such as extra tags for selective 
affinity chromatography and also multiple purification steps 
with limited purification yields (maximum 33%). Fusion to 
heterodimeric Fc fragments can present the fusion partner in its 
natural monomeric form for monomeric proteins and peptides as 
well as natural heterodimeric forms for heterodimeric proteins, 
rather than the artificial homodimeric form for wild-type Fc 
fragments (Figure  4E). This heterodimeric Fc capability will 
facilitate the development of the next generation of Fc-fused 
proteins that maintain full function of the fusion partner, while 
retaining the Fc-mediated extended half-life and immune effec-
tor functions. The reduced binding valency might further help 
to reduce target receptor-mediated clearance. Particularly, in 
tumor-targeting IgG-based immunocytokines, the heterodimeric 
Fc-fused cytokines, in their natural forms, improve tumor tissue 
accumulation by reducing associations with immune cells, and 
thereby minimizing systemic toxicity. This facilitates their devel-
opment as therapeutic agents. Some heterodimeric Fc-based 
IgG-fused immunocytokines are now in clinical trials and many 
more are expected to be developed.
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